BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | |||
|---|---|---|---|---|---|---|
Jul. 17, 2024 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Sep. 30, 2024 |
Sep. 30, 2023 |
Dec. 31, 2023 |
|
| Property, Plant and Equipment [Line Items] | ||||||
| Common stock, shares authorized | 950,000,000 | 950,000,000 | 950,000,000 | |||
| Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||
| Preferred stock, shares authorized | 20,000,000 | 20,000,000 | 20,000,000 | |||
| Preferred stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||
| Current operating activities | $ 2,500,000 | |||||
| Sale of common stock | 6,000,000 | |||||
| Current operating activities | (1,213,127) | $ (829,886) | ||||
| Cash on hand | $ 1,218,160 | $ 1,218,160 | ||||
| Economic life of the patent | 10 years | 10 years | ||||
| Research and development costs | $ 66,551 | $ 80,858 | $ 223,660 | $ 300,586 | ||
| Brachytherapy Product Line [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Current operating activities | $ 5,000,000 | |||||
| Offering term | Over the next 12 to 48 months, the Company believes it will cost approximately $9 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, and clinical trials; (3) activate several regional clinics to administer IsoPet® across the county; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. The proceeds to be raised from the Regulation A+ Offerings will be used to continue to fund this development. | |||||
| Radionuclide Therapy Product Line [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Current operating activities | $ 2,500,000 | |||||
| Offering term | Over the next 36 months, the Company believes it will cost approximately $8.0 to $9.0 million to: (1) fund the FDA approval process to conduct human clinical trials; (2) conduct Phase I, pilot, clinical trials; (3) activate several regional clinics to administer IsoPet® across the U.S.; (4) create an independent production center within the current production site to create a template for future international manufacturing; and (5) initiate regulatory approval processes outside of the United States. | |||||
| Warrant [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Number of warrants issued | 7,000,000 | 7,000,000 | 18,797,000 | |||
| Common Stock [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Number of common stock shares issued, value | $ 839,000 | |||||
| Number of common stock shares issued, shares | 13,000,000 | |||||
| Common Stock [Member] | Maximum [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Number of common stock shares issued, value | $ 60,000,000 | |||||
| Private Placement [Member] | ||||||
| Property, Plant and Equipment [Line Items] | ||||||
| Number of common stock shares issued, value | $ 1,179,245 | |||||
| Number of common stock shares issued, shares | 16,132,000 | |||||